New drug cocktail aims to tackle Hard-to-Treat breast cancer
NCT ID NCT06959537
First seen Nov 10, 2025 · Last updated Jun 20, 2026 · Updated 29 times
Summary
This early-phase trial is testing a new combination of three drugs—cyclophosphamide, axatilimab, and retifanlimab—in people with metastatic triple negative breast cancer that has stopped responding to standard treatments. The goal is to find the safest and most effective doses. The study is currently recruiting 24 participants at M.D. Anderson Cancer Center.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The University of Texas M. D. Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cyclophosphamide, axatilimab, and retifanlimab
What this could lead to
If this works, it could point toward a new treatment option for metastatic triple negative breast cancer that is no longer responding to standard therapies.
What could go wrong
This is a very early phase 1 trial with only 24 participants, so it is primarily testing safety and dosing. The combination may not prove effective or could cause significant side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.